Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva, Sandoz, Mylan, Pfizer…Who Sees Value In The US Biosimilars Market?

Executive Summary

While 2018 was a record year for US biosimilar approvals and launches, companies are still struggling for market share in certain therapies and facing obstacles in getting their products over the line. Generics Bulletin rounds up where the leading players stand, ahead of financial results being published in the coming days and weeks.
Advertisement

Related Content

Teva, Sandoz, Mylan, Pfizer…Who Sees Value In The US Biosimilars Market?
Samsung Bioepis’ Trastuzumab Biosimilar Is Third Cleared By FDA – But The Market Hasn’t Formed Yet
Pfizer Axes Staff And Five Pre-Clinical Biosimilars To Fund Late-Stage Innovative Programs
Coherus BioSciences Outlines ‘Very Different Approach’ And Raises Another US$75m To Launch Udenyca
US Pricing Pressures Have Stabilized, Insists Teva Chief
Sandoz Forms Insulin Biosimilars Deal With Gan & Lee
FDA’s Gottlieb Rolls Out A Raft Of Biosimilar Reforms
Amgen has plans for biosimilar infliximab
Biocon confirms US Neulasta rival launch
Sandoz and Biocon strike global biosimilars alliance

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

GB140017

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel